Navigation Links
Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
Date:11/11/2013

the number of unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The clinical utility and cost effectiveness of the GEC have been demonstrated in studies published in peer-reviewed journals and the clinical validity of the GEC has been demonstrated in a study published in The New England Journal of Medicine in 2012. Since the commercial launch of Afirma in January 2011, Veracyte has processed over 50,000 FNA samples for evaluation using Afirma and has performed more than 10,000 GECs to resolve indeterminate cytopathology results. Veracyte has obtained positive coverage decisions for Afirma from Aetna, Humana, Medicare and UnitedHealthcare. Collectively, these payers represent more than 100 million covered lives. Afirma is marketed and sold in the United States through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi. Veracyte estimates the global market for Afirma to be $800 million. The company intends to expand its molecular cytology franchise to other clinical areas and is in late biomarker discovery for its first product in pulmonology.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to the estimated size of the global market for Afirma and to our intent to expand our molecular cytology business into other clinical areas. Forward-looking statements are indicated by words such as "believes," "expects" and "intends," and involve risks and uncertainties, which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to: our limited operating history and history of losses; our ability to increase
'/>"/>

SOURCE Veracyte
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Veracyte, Inc. Announces Pricing of Initial Public Offering
2. Harwood Feffer LLP Announces Investigation of Santarus, Inc.
3. Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
4. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
5. IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
6. Intrexon Announces Third Quarter Financial Results
7. Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
8. Pro-Dex, Inc. Announces Fiscal 2014 First Quarter Financial Results Conference Call And Webcast
9. DURECT Announces Proposed Public Offering of Common Stock
10. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
11. Star Scientific Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
(Date:7/14/2014)... Encino, CA (PRWEB) July 14, 2014 ... Dental Group is now offering Lumineers and ... more extensive procedures that require more preparation and greater ... use porcelain tooth-shaped shells to conceal visible flaws on ... Dr. Sabbagh-Fard work closely with patients to ensure they ...
(Date:7/14/2014)... Barbara Bronson Gray ... News) -- New research suggests that a faltering sense ... disease, and that an inexpensive, low-tech smell test could ... In two different studies, the decreased ability to identify ... function and progression to Alzheimer,s disease. "We,re trying ...
(Date:7/14/2014)... Kathleen Doheny HealthDay ... Losing a spouse may be linked to multiple health issues, ... study. For certain seniors, widowhood may even delay dementia, ... memory problem, losing the spouse was associated with a later ... married," said study researcher Dr. Bryan Woodruff. Woodruff, ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... BOSTON, Aug. 6 The Center for Business Intelligence (CBI), a ... which includes Dr. Paul Tang, Vice President and Chief Medical Information ... inaugural Access Federal Stimulus Incentives for Electronic Health Records ... in Alexandria, VA, on September 24-25, 2009. , ...
... unaware there is no cure, survey finds , THURSDAY, Aug. ... mistakenly believe that daily medicine can be taken to prevent ... a widespread lack of knowledge and awareness about food allergy ... adults also found that nearly half of respondents incorrectly believed ...
... , , , , ... Wyse Technology , the global leader in thin computing and ... . Kool Smiles is a rapidly-growing company whose mission is ... Since opening its first office in 2002 in Atlanta, GA, the ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... MCLEAN, Va., Aug. 6 Sunrise Senior Living, Inc. ... data for the second quarter of 2009. Sunrise will host ... a.m. ET, to discuss the financial results. , , ... of progress in expense controls. In recent weeks we have seen ...
... Greece, August 6 , - Not for Release, Publication or Distribution ... Canada, Australia, South Africa or Japan or, any Other ... Unlawful, - This Announcement is not a Prospectus and is not ... Offer to buy any Securities in the United States or, ...
Cached Medicine News:Health News:CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 2Health News:Food Allergy Facts Need More Focus 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 3Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 4Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 5Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 2Health News:Sunrise Reports Financial Results for Second-Quarter 2009 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 4Health News:Sunrise Reports Financial Results for Second-Quarter 2009 5Health News:Sunrise Reports Financial Results for Second-Quarter 2009 6Health News:Sunrise Reports Financial Results for Second-Quarter 2009 7Health News:Sunrise Reports Financial Results for Second-Quarter 2009 8Health News:Sunrise Reports Financial Results for Second-Quarter 2009 9Health News:Sunrise Reports Financial Results for Second-Quarter 2009 10Health News:Sunrise Reports Financial Results for Second-Quarter 2009 11Health News:Sunrise Reports Financial Results for Second-Quarter 2009 12Health News:Sunrise Reports Financial Results for Second-Quarter 2009 13Health News:Sunrise Reports Financial Results for Second-Quarter 2009 14Health News:Sunrise Reports Financial Results for Second-Quarter 2009 15Health News:Sunrise Reports Financial Results for Second-Quarter 2009 16Health News:Sunrise Reports Financial Results for Second-Quarter 2009 17Health News:Sunrise Reports Financial Results for Second-Quarter 2009 18Health News:Sunrise Reports Financial Results for Second-Quarter 2009 19Health News:Sunrise Reports Financial Results for Second-Quarter 2009 20Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 2Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: